A Primer on Parenteral Radiopaque Contrast Agents

Total Page:16

File Type:pdf, Size:1020Kb

A Primer on Parenteral Radiopaque Contrast Agents THE UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER COLLEGE OF PHARMACY ALBUQUERQUE, NEW MEXICO Correspondence Continuing Education Courses For Nuclear Pharmacists and Nuclear Medicine Professionals VOLUME X, NUMBER 2 A Primer on Parenteral Radiopaque Contrast Agents By Peter Dawson, BSc, PhD, CPhys, MBBS, FRCP, FRCR University College London Hospitals London, United Kingdom The University of New Mexico Health Sciences Center College of Pharmacy is accredited by the American Council on Pharmaceutical Education as a provider of continuing pharmaceutical education. Program No. 039-000-02-005-H04. 3.0 Contact Hours or .30 CEUs A Primer on Parenteral Radiopaque Contrast Agents By: Peter Dawson, BSc, PhD, CPhys, MBBS, FRCP, FRCR University College London Hospitals London, United Kingdom Coordinating Editor and Director of Pharmacy Continuing Education William B. Hladik III, MS, RPh, FASHP, FAPhA College of Pharmacy University of New Mexico Health Sciences Center Managing Editor Julliana Newman, ELS Wellman Publishing, Inc. Albuquerque, New Mexico Editorial Board George H. Hinkle, MS, RPh, BCNP, FASHP, FAPhA Jeffrey P. Norenberg, MS, PharmD, BCNP, FASHP Neil A. Petry, MS, RPh, BCNP, FAPhA Laura L. Boles Ponto, PhD, RPh Timothy M. Quinton, PharmD, MS, RPh, BCNP, FAPhA Guest Reviewer Robert L. Siegle, MD Professor and Chairman Department of Radiologic Sciences Drexel University College of Medicine 245 North 15th Street, MailStop 206 Philadelphia, PA 19102-1192 While the advice and information in this publication are believed to be true and accurate at press time, the author(s), editors, or the publisher cannot accept any legal responsibility for any errors or omissions that may be made. The publisher makes no war- ranty, express or implied, with respect to the material contained herein. Copyright 2003 University of New Mexico Health Sciences Center Pharmacy Continuing Education Albuquerque, New Mexico A PRIMER ON PARENTERAL RADIOPAQUE CONTRAST AGENTS STATEMENT OF OBJECTIVES The purpose of this continuing education lesson is to increase the reader’s knowledge and understanding of the clinical applications of parenteral radiopaque contrast agents. Upon completion of this lesson, the reader should be able to: 1. Discuss in broad terms the clinical applications of contrast agents. 2. Explain the significance of iodine, its use in radiopaque contrast agents and the variations of carrier molecules used to deliver it. 3. Explain why relatively low osmolality and low chemotoxicity are desirable characteristics of contrast agents and describe how the structure of the contrast molecule influences these two characteristics. 4. Identify the risk factors for major reactions to contrast media and critically discuss pre-treatment protocols that minimize the probability of occurrence of such reactions. 5. Discuss the clinical manifestations and incidence of side effects and adverse reactions known to be associated with contrast media and identify their important causes and mediating factors. 6. Describe the manifestations and treatment of anaphylactoid reactions. 7. Discuss, in descriptive terms, contrast agent pharmacokinetics. COURSE OUTLINE VII. ANAPHYLACTOID/ IDIOSYNCRATIC I. INTRODUCTION REACTIONS A. The Term "Contrast" A. Prophylaxis of B. Historical Development Anaphylactoid Reactions B. Treatment of II. DISADVANTAGES OF Anaphylactoid Reactions CONVENTIONAL IONIC CONTRAST AGENTS VIII. A NOTE ON THE CLINICAL USE OF CONTRAST AGENTS III. LOW-OSMOLAR AGENTS A. Non-Ionic Agents IX. A BRIEF NOTE ON B. Monoacid Dimeric Agents COAGULATION AND C. Non-Ionic Dimeric PLATELETS Contrast Agents X. THE METFORMIN ISSUE IV. CONTRAST AGENT TOXICITY – THE CONCEPT XI. CONCLUSIONS OF MOLECULAR TOXICITY XII. REFERENCES V. PHARMACOKINETICS XIII. QUESTIONS VI. OSMOLALITY, MOLECULAR TOXICITY, ORGAN SPECIFIC TOXICITIES AND HIGH DOSE TOXICITY OF CONTRAST AGENTS 1 A PRIMER ON PARENTERAL an image is not the norm and usually contrast RADIOPAQUE CONTRAST AGENTS agents may be relied upon to improve the images and their information content by By: enhancement of relevant image contrast. Peter Dawson, BSc, PhD, Sometimes reference is made to "nega- CPhys, MBBS, FRCP, FRCR tive" and "positive" contrast agents. This fre- University College London Hospitals quently causes confusion. As far as x-ray London, United Kingdom contrast agents are concerned "positive" agents are those that increase the absorption of x-rays while "negative" agents decrease x- INTRODUCTION ray absorption. The iodinated agents are pos- The Term "Contrast" itive contrast agents because iodine atoms, The word "contrast" should be explained which are incorporated into their chemical at the outset so that its use in the terms "con- structures, are efficient absorbers of x-rays in trast agent" and "contrast medium" is clearly the diagnostic energy range. (So, incidental- understood. The term contrast is a photo- ly, are the barium atoms in contrast agents graphic or, more generally, a medical imag- used for studies of the gut.) Gases, such as ing term. Contrast in an image of any kind is air or CO2, on the other hand, are negative what allows detail to be discerned between agents as they do not significantly absorb x- two or more adjacent regions of the image. rays and instead allow them to pass more Black chalk on a blackboard cannot be seen readily. Thus, these gases may be very useful because there is no contrast, however, white as well, for example, in providing the con- chalk on the same blackboard produces high trast necessary to differentiate the gastroin- contrast that is readily apparent to the human testinal tract from other adjacent anatomical eye. Fortunately, there is some natural con- structures. trast in medical images of all kinds. If there were no contrast, medical images would be Historical Development of little value. Thus in a computed tomogra- Without the availability of good and rel- phy (CT) image (which has far better resolu- atively safe intravascular contrast agents, tion and display of contrast than any ordi- diagnostic radiology would not have come to nary x-ray film) darker blood vessels may be occupy the central position it currently does seen crossing a lighter liver. A tumor in the in the medical diagnostic process. The great liver will frequently, but not reliably, be bulk of "interventional radiology" proce- darker than normal liver and so will be read- dures would certainly not have emerged ily apparent because of the natural contrast without the development of the contrast associated with this imaging technology. The agent industry. The fact that most radiolo- purpose of a contrast-enhancing agent ("con- gists often take the contribution of the con- trast agent," "contrast medium") is, as the trast agent largely for granted may be seen as name suggests, to enhance such natural con- a tribute to the excellent qualities associated trast and render tissues of interest – usually with the current generation of these. those with pathology – more clearly visible. The need for intravascular contrast Now it must be said immediately that con- agents was realized very early in the history trast agents do not always succeed optimally of radiology, as witnessed by the perform- in this aim. Sometimes a tumor, to take the ance of angiograms on an amputated hand same example, may actually become less and on a cadaver kidney by Haschek and clearly visible after administration of a con- Lindenthal1 and Hicks and Addison,2 respec- trast agent. Clearly, much depends on the tively, both within a month of Roentgen’s blood supply and other structural character- report of the discovery of x-rays. The radio- istics of normal tissue and tumor. However, opaque suspensions used for these classic such worsening of the observed contrast in studies were not clinically practicable but the 2 achievements were remarkable. In subse- tional cell carcinoma,8 while local injections quent years, various agents were used to into breast and maxillary sinuses have been opacify the gastrointestinal tract, the bladder, followed by carcinoma developing at these ureters, renal pelvis and lymphatics by direct sites.9 Perivascular extravasation of contrast injection, but little progress was made with is associated with local granuloma forma- the development of agents which could be tion. safely injected into the circulation. While inorganic iodide solutions were Berberich and Hirsch3 used a strontium too toxic for general use, it was realized that bromide solution for the opacification of the elemental iodine is certainly an outstanding- peripheral veins and, in the same year, ly good choice for x-ray absorption. The K- Osborne, et al4 at the Mayo Clinic noted shell electron binding energy is approxi- opacification of the bladder in patients treat- mately 33 KeV, which is lower than, but ed with intravenous (IV) solutions of sodium close to, the mean energy used in diagnostic iodide for syphilis. They had unwittingly x-ray work, thereby maximizing the cross- performed the first IV urogram. However, section for photoelectric interactions. All the delineation of the upper urinary tract was other considerations such as chemistry aside, poor and sodium iodide solutions were rather iodine is an ideal choice of element for use in toxic for general use for urography. Enough an x-ray contrast agent at the energies typi- interest was generated, however, for Brooks5 cally used clinically. Barium, incidentally, to try sodium iodide solutions for peripheral used in studies of the gastrointestinal tract is angiography and in 1927
Recommended publications
  • Wo 2009/081169 A2
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date PCT 2 July 2009 (02.07.2009) WO 2009/081169 A2 (51) International Patent Classification: KJELLSON, Fred [SE/SE]; IoPharma Technologies AB, A61K 49/04 (2006.01) Ideon Science Park, Ole Romers Vag 12, SE-223 70 Lund (SE). KLAVENESS, J o [NO/SE]; IoPharma Technologies (21) International Application Number: AB, Ideon Science Park, Ole Romers Vag 12, SE-223 70 PCT/GB2008/004268 Lund (SE). (22) International Filing Date: (74) Agent: KIDD, Sara; Frank B. Dehn 6 Co., St. Bride's 22 December 2008 (22.12.2008) House, 10 Salisbury Square, London EC4Y 8ID (GB). (25) Filing Language: English (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, (26) Publication Language: English AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, (30) Priority Data: EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, 0725070.7 21 December 2007 (21.12.2007) GB IL, IN, IS, IP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, (71) Applicant (for all designated States except US): IO- LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, PHARMA TECHNOLOGIES AB [SE/SE]; Ideon MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, Science Park, Ole Romers Vag 12, SE-223 70 Lund (SE).
    [Show full text]
  • AHFS Pharmacologic-Therapeutic Classification System
    AHFS Pharmacologic-Therapeutic Classification System Abacavir 48:24 - Mucolytic Agents - 382638 8:18.08.20 - HIV Nucleoside and Nucleotide Reverse Acitretin 84:92 - Skin and Mucous Membrane Agents, Abaloparatide 68:24.08 - Parathyroid Agents - 317036 Aclidinium Abatacept 12:08.08 - Antimuscarinics/Antispasmodics - 313022 92:36 - Disease-modifying Antirheumatic Drugs - Acrivastine 92:20 - Immunomodulatory Agents - 306003 4:08 - Second Generation Antihistamines - 394040 Abciximab 48:04.08 - Second Generation Antihistamines - 394040 20:12.18 - Platelet-aggregation Inhibitors - 395014 Acyclovir Abemaciclib 8:18.32 - Nucleosides and Nucleotides - 381045 10:00 - Antineoplastic Agents - 317058 84:04.06 - Antivirals - 381036 Abiraterone Adalimumab; -adaz 10:00 - Antineoplastic Agents - 311027 92:36 - Disease-modifying Antirheumatic Drugs - AbobotulinumtoxinA 56:92 - GI Drugs, Miscellaneous - 302046 92:20 - Immunomodulatory Agents - 302046 92:92 - Other Miscellaneous Therapeutic Agents - 12:20.92 - Skeletal Muscle Relaxants, Miscellaneous - Adapalene 84:92 - Skin and Mucous Membrane Agents, Acalabrutinib 10:00 - Antineoplastic Agents - 317059 Adefovir Acamprosate 8:18.32 - Nucleosides and Nucleotides - 302036 28:92 - Central Nervous System Agents, Adenosine 24:04.04.24 - Class IV Antiarrhythmics - 304010 Acarbose Adenovirus Vaccine Live Oral 68:20.02 - alpha-Glucosidase Inhibitors - 396015 80:12 - Vaccines - 315016 Acebutolol Ado-Trastuzumab 24:24 - beta-Adrenergic Blocking Agents - 387003 10:00 - Antineoplastic Agents - 313041 12:16.08.08 - Selective
    [Show full text]
  • Xx250 Spc 2015 Uk
    SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT XENETIX 250 (250 mgI/ml) Solution for injection. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION per ml 50 ml 100 ml 200 ml 500 ml Iobitridol (INN) 548.4 mg 27.42 g 54.84 g 109.68 g 274.2 g Iodine corresponding to 250 mg 12.5 g 25 g 50 g 125 g Excipient with known effect : Sodium (up to 3.5 mg per 100 mL). For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Solution for injection. Clear, colourless to pale yellow solution 4. CLINICAL PARTICULARS 4.1. Therapeutic indications For adults and children undergoing: . whole-body CT . venography . intra-arterial digital subtraction angiography . ERP/ERCP This medicinal product is for diagnostic use only. 4.2. Posology and method of administration The dosage may vary depending on the type of examination, the age, weight, cardiac output and general condition of the patient and the technique used. Usually the same iodine concentration and volume are used as with other iodinated X-ray contrast in current use. As with all contrast media, the lowest dose necessary to obtain adequate visualisation should be used. Adequate hydration should be assured before and after administration as for other contrast media. As a guideline, the recommended dosages are as follows: Indications Recommended dosage Whole-body CT The doses of contrast medium and the rates of administration depend on the organs under investigation, the diagnostic problem and, in particular, the different scan and image-reconstruction times of the scanners in use.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • Pharmacologyonline 2: 727-753 (2010) Ewsletter Bradu and Rossini
    Pharmacologyonline 2: 727-753 (2010) ewsletter Bradu and Rossini COTRAST AGETS - IODIATED PRODUCTS. SECOD WHO-ITA / ITA-OMS 2010 COTRIBUTIO O AGGREGATE WHO SYSTEM-ORGA CLASS DISORDERS AD/OR CLUSTERIG BASED O REPORTED ADVERSE REACTIOS/EVETS Dan Bradu and Luigi Rossini* Servizio Nazionale Collaborativo WHO-ITA / ITA-OMS, Università Politecnica delle Marche e Progetto di Farmacotossicovigilanza, Azienda Ospedaliera Universitaria Ospedali Riuniti di Ancona, Regione Marche, Italia Summary From the 2010 total basic adverse reactions and events collected as ADRs preferred names in the WHO-Uppsala Drug Monitoring Programme, subdivided in its first two twenty years periods as for the first seven iodinated products diagnostic contrast agents amidotrizoate, iodamide, iotalamate, iodoxamate, ioxaglate, iohexsol and iopamidol, their 30 WHO-system organ class disorders (SOCDs) aggregates had been compared. Their common maximum 97% levels identified six SOCDs only, apt to evaluate the most frequent single ADRs for each class, and their percentual normalization profiles for each product. The WILKS's chi square statistics for the related contingency tables, and Gabriel’s STP procedure applied to the extracted double data sets then produced profile binary clustering, as well as Euclidean confirmatory plots. They finally showed similar objectively evaluated autoclassificative trends of these products, which do not completely correspond to their actual ATC V08A A, B and C subdivision: while amidotrizoate and iotalamate, and respectively iohesol and iopamidol are confirmed to belong to the A and B subgroups, ioxaglate behaves fluctuating within A, B and C, but iodamide looks surprizingly, constantly positioned together with iodoxamate as binary/ternary C associated. In view of the recent work of Campillos et al (Science, 2008) which throws light on the subject, the above discrepancies do not appear anymore unexpected or alarming.
    [Show full text]
  • Drug-Induced Anaphylaxis in China: a 10 Year Retrospective Analysis of The
    Int J Clin Pharm DOI 10.1007/s11096-017-0535-2 RESEARCH ARTICLE Drug‑induced anaphylaxis in China: a 10 year retrospective analysis of the Beijing Pharmacovigilance Database Ying Zhao1,2,3 · Shusen Sun4 · Xiaotong Li1,3 · Xiang Ma1 · Huilin Tang5 · Lulu Sun2 · Suodi Zhai1 · Tiansheng Wang1,3,6 Received: 9 May 2017 / Accepted: 19 September 2017 © The Author(s) 2017. This article is an open access publication Abstract Background Few studies on the causes of (50.1%), mucocutaneous (47.4%), and gastrointestinal symp- drug-induced anaphylaxis (DIA) in the hospital setting are toms (31.3%). A total of 249 diferent drugs were involved. available. Objective We aimed to use the Beijing Pharma- DIAs were mainly caused by antibiotics (39.3%), traditional covigilance Database (BPD) to identify the causes of DIA Chinese medicines (TCM) (11.9%), radiocontrast agents in Beijing, China. Setting Anaphylactic case reports from (11.9%), and antineoplastic agents (10.3%). Cephalospor- the BPD provided by the Beijing Center for Adverse Drug ins accounted for majority (34.5%) of antibiotic-induced Reaction Monitoring. Method DIA cases collected by the anaphylaxis, followed by fuoroquinolones (29.6%), beta- BPD from January 2004 to December 2014 were adjudi- lactam/beta-lactamase inhibitors (15.4%) and penicillins cated. Cases were analyzed for demographics, causative (7.9%). Blood products and biological agents (3.1%), and drugs and route of administration, and clinical signs and plasma substitutes (2.1%) were also important contributors outcomes. Main outcome measure Drugs implicated in DIAs to DIAs. Conclusion A variety of drug classes were impli- were identifed and the signs and symptoms of the DIA cases cated in DIAs.
    [Show full text]
  • NON-HAZARDOUS CHEMICALS May Be Disposed of Via Sanitary Sewer Or Solid Waste
    NON-HAZARDOUS CHEMICALS May Be Disposed Of Via Sanitary Sewer or Solid Waste (+)-A-TOCOPHEROL ACID SUCCINATE (+,-)-VERAPAMIL, HYDROCHLORIDE 1-AMINOANTHRAQUINONE 1-AMINO-1-CYCLOHEXANECARBOXYLIC ACID 1-BROMOOCTADECANE 1-CARBOXYNAPHTHALENE 1-DECENE 1-HYDROXYANTHRAQUINONE 1-METHYL-4-PHENYL-1,2,5,6-TETRAHYDROPYRIDINE HYDROCHLORIDE 1-NONENE 1-TETRADECENE 1-THIO-B-D-GLUCOSE 1-TRIDECENE 1-UNDECENE 2-ACETAMIDO-1-AZIDO-1,2-DIDEOXY-B-D-GLYCOPYRANOSE 2-ACETAMIDOACRYLIC ACID 2-AMINO-4-CHLOROBENZOTHIAZOLE 2-AMINO-2-(HYDROXY METHYL)-1,3-PROPONEDIOL 2-AMINOBENZOTHIAZOLE 2-AMINOIMIDAZOLE 2-AMINO-5-METHYLBENZENESULFONIC ACID 2-AMINOPURINE 2-ANILINOETHANOL 2-BUTENE-1,4-DIOL 2-CHLOROBENZYLALCOHOL 2-DEOXYCYTIDINE 5-MONOPHOSPHATE 2-DEOXY-D-GLUCOSE 2-DEOXY-D-RIBOSE 2'-DEOXYURIDINE 2'-DEOXYURIDINE 5'-MONOPHOSPHATE 2-HYDROETHYL ACETATE 2-HYDROXY-4-(METHYLTHIO)BUTYRIC ACID 2-METHYLFLUORENE 2-METHYL-2-THIOPSEUDOUREA SULFATE 2-MORPHOLINOETHANESULFONIC ACID 2-NAPHTHOIC ACID 2-OXYGLUTARIC ACID 2-PHENYLPROPIONIC ACID 2-PYRIDINEALDOXIME METHIODIDE 2-STEP CHEMISTRY STEP 1 PART D 2-STEP CHEMISTRY STEP 2 PART A 2-THIOLHISTIDINE 2-THIOPHENECARBOXYLIC ACID 2-THIOPHENECARBOXYLIC HYDRAZIDE 3-ACETYLINDOLE 3-AMINO-1,2,4-TRIAZINE 3-AMINO-L-TYROSINE DIHYDROCHLORIDE MONOHYDRATE 3-CARBETHOXY-2-PIPERIDONE 3-CHLOROCYCLOBUTANONE SOLUTION 3-CHLORO-2-NITROBENZOIC ACID 3-(DIETHYLAMINO)-7-[[P-(DIMETHYLAMINO)PHENYL]AZO]-5-PHENAZINIUM CHLORIDE 3-HYDROXYTROSINE 1 9/26/2005 NON-HAZARDOUS CHEMICALS May Be Disposed Of Via Sanitary Sewer or Solid Waste 3-HYDROXYTYRAMINE HYDROCHLORIDE 3-METHYL-1-PHENYL-2-PYRAZOLIN-5-ONE
    [Show full text]
  • Page 1 Note: Within Nine Months from the Publication of the Mention
    Europäisches Patentamt (19) European Patent Office & Office européen des brevets (11) EP 1 411 992 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 49/04 (2006.01) A61K 49/18 (2006.01) 13.12.2006 Bulletin 2006/50 (86) International application number: (21) Application number: 02758379.8 PCT/EP2002/008183 (22) Date of filing: 23.07.2002 (87) International publication number: WO 2003/013616 (20.02.2003 Gazette 2003/08) (54) IONIC AND NON-IONIC RADIOGRAPHIC CONTRAST AGENTS FOR USE IN COMBINED X-RAY AND NUCLEAR MAGNETIC RESONANCE DIAGNOSTICS IONISCHES UND NICHT-IONISCHES RADIOGRAPHISCHES KONTRASTMITTEL ZUR VERWENDUNG IN DER KOMBINIERTEN ROENTGEN- UND KERNSPINTOMOGRAPHIEDIAGNOSTIK SUBSTANCES IONIQUES ET NON-IONIQUES DE CONTRASTE RADIOGRAPHIQUE UTILISEES POUR ETABLIR DES DIAGNOSTICS FAISANT APPEL AUX RAYONS X ET A L’IMAGERIE PAR RESONANCE MAGNETIQUE (84) Designated Contracting States: (74) Representative: Minoja, Fabrizio AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Bianchetti Bracco Minoja S.r.l. IE IT LI LU MC NL PT SE SK TR Via Plinio, 63 20129 Milano (IT) (30) Priority: 03.08.2001 IT MI20011706 (56) References cited: (43) Date of publication of application: EP-A- 0 759 785 WO-A-00/75141 28.04.2004 Bulletin 2004/18 US-A- 5 648 536 (73) Proprietor: BRACCO IMAGING S.p.A. • K HERGAN, W. DORINGER, M. LÄNGLE W.OSER: 20134 Milano (IT) "Effects of iodinated contrast agents in MR imaging" EUROPEAN JOURNAL OF (72) Inventors: RADIOLOGY, vol. 21, 1995, pages 11-17, • AIME, Silvio XP002227102 20134 Milano (IT) • K.M.
    [Show full text]
  • Iodination Process Verfahren Zur Iodierung Procede D’Iodation
    Europäisches Patentamt *EP000828705B1* (19) European Patent Office Office européen des brevets (11) EP 0 828 705 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.7: C07C 231/12, C07C 237/46 of the grant of the patent: 23.08.2000 Bulletin 2000/34 (86) International application number: PCT/GB96/01219 (21) Application number: 96914332.0 (87) International publication number: (22) Date of filing: 21.05.1996 WO 96/37461 (28.11.1996 Gazette 1996/52) (54) IODINATION PROCESS VERFAHREN ZUR IODIERUNG PROCEDE D’IODATION (84) Designated Contracting States: (74) Representative: Skailes, Humphrey John et al DE FR IT PT Frank B. Dehn & Co., European Patent Attorneys, (30) Priority: 24.05.1995 US 449272 179 Queen Victoria Street 06.06.1995 GB 9511367 London EC4V 4EL (GB) (43) Date of publication of application: (56) References cited: 18.03.1998 Bulletin 1998/12 US-A- 5 013 865 (73) Proprietor: NYCOMED IMAGING AS • TETRAHEDRON LETT. (1989), 30(13), 1649-50 0401 Oslo 4 (NO) CODEN: TELEAY;ISSN: 0040-4039, 1989, XP000572794 SHONO, TATSUYA ET AL: (72) Inventors: "Electroorganic chemistry. 117. Aromatic • WISTRAND, Lars-Göran iodination by positive iodine active species N-0401 Oslo (NO) generated by anodic oxidation in trimethyl • GOLMAN, Klaes orthoformate" cited in the application N-0401 Oslo (NO) • J. AM. CHEM. SOC. (1976), 98(6), 1515-19 • RADNER, Finn CODEN: JACSAT, 1976, XP000573922 MILLER, N-0401 Oslo (NO) LARRY L. ET AL: "Scope and mechanism of aromatic iodination with electrochemically generated iodine(I)" Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted.
    [Show full text]
  • ACR Manual on Contrast Media
    ACR Manual On Contrast Media 2021 ACR Committee on Drugs and Contrast Media Preface 2 ACR Manual on Contrast Media 2021 ACR Committee on Drugs and Contrast Media © Copyright 2021 American College of Radiology ISBN: 978-1-55903-012-0 TABLE OF CONTENTS Topic Page 1. Preface 1 2. Version History 2 3. Introduction 4 4. Patient Selection and Preparation Strategies Before Contrast 5 Medium Administration 5. Fasting Prior to Intravascular Contrast Media Administration 14 6. Safe Injection of Contrast Media 15 7. Extravasation of Contrast Media 18 8. Allergic-Like And Physiologic Reactions to Intravascular 22 Iodinated Contrast Media 9. Contrast Media Warming 29 10. Contrast-Associated Acute Kidney Injury and Contrast 33 Induced Acute Kidney Injury in Adults 11. Metformin 45 12. Contrast Media in Children 48 13. Gastrointestinal (GI) Contrast Media in Adults: Indications and 57 Guidelines 14. ACR–ASNR Position Statement On the Use of Gadolinium 78 Contrast Agents 15. Adverse Reactions To Gadolinium-Based Contrast Media 79 16. Nephrogenic Systemic Fibrosis (NSF) 83 17. Ultrasound Contrast Media 92 18. Treatment of Contrast Reactions 95 19. Administration of Contrast Media to Pregnant or Potentially 97 Pregnant Patients 20. Administration of Contrast Media to Women Who are Breast- 101 Feeding Table 1 – Categories Of Acute Reactions 103 Table 2 – Treatment Of Acute Reactions To Contrast Media In 105 Children Table 3 – Management Of Acute Reactions To Contrast Media In 114 Adults Table 4 – Equipment For Contrast Reaction Kits In Radiology 122 Appendix A – Contrast Media Specifications 124 PREFACE This edition of the ACR Manual on Contrast Media replaces all earlier editions.
    [Show full text]
  • Biosimilar Branded Iodinated Contrast Agents Related to the Largest Number of Reports to the Who-Pharmacovigilance System Over the First 40 Years of the Programme
    Pharmacologyonline 2: 929-962 (2011) Newsletter Bradu and Rossini BIOSIMILAR BRANDED IODINATED CONTRAST AGENTS RELATED TO THE LARGEST NUMBER OF REPORTS TO THE WHO-PHARMACOVIGILANCE SYSTEM OVER THE FIRST 40 YEARS OF THE PROGRAMME. FIFTH WHO-ITA/ITA-OMS 2010-2011 CONTRIBUTION Dan Bradu and Luigi Rossini* Servizio Nazionale collaborativo WHO-ITA/ITA-OMS, Universita’ Politecnica delle Marche e Progetto di Farmacotossicovigilanza pre-, post-marketing, Azienda Ospedaliera Universitaria Ospedali Riuniti di Ancona, Regione Marche, Italia Summary Analysis of the side-events, and suspicious or confirmed adverse drug reactions (SADRs), accounting for a total of 67,232 reports, based on the model and on a Matlab program (as described in the fourth contribution of our current series) showed broadly inhomogeneous profiles of all of the 10 products categorized as “biosimilar” that have been the object of the largest number of reports in the first 40 years of the WHO Pharmacovigilance Programme. The analysis highlighted striking differences both when they were subdivided into system-organ class disorders (SOCDs) or studied together, and when they were analyzed in terms of five pairs of biosimilars and their respective, agreed, generic reference products. These conclusions add to the data, already reported by the authors, of the preclinical experiments and the pre-marketing conventional standardized clinical trials regulations. Key words: WHO International Drug Monitoring, Pharmacovigilance Programme. Correlation objective autoclassificative and confirmatory clustering comparisons between couples of ATC- 929 Pharmacologyonline 2: 929-962 (2011) Newsletter Bradu and Rossini V08A-A 8 Amidotrizoate, Iotalamate, Ioxitalamate and Metrizoate, and ATC-V08A-B 2 Ioxaglate “biosimilars”. ----------------------------------------------------------------------------------------------------------------------- -* Corresponding author, retired October 31, 2008.
    [Show full text]